Speaker Profile

Ph.D., Senior Manager, Immunooncology and Vaccines, JSR Life Sciences

Dr. Pirouz M Daftarian leads a team of scientists focusing on T cell exhaustion, single cell-based T cell analysis, and biomarkers of responsiveness to current IO therapies. Pirouz serves as the Senior Manager of Applications, Immunooncology and Vaccines at JSR Life Sciences LLC, overseas the global immunooncology R&D of the company and its affiliates, serves as a volunteer adjunct faculty at University of Miami Pirouz, and a reviewer of multiple cancer immunology and vaccine journals. He has shepherded R&D operations in biotech companies, and academia, acted as DOD and NIH intramural panel reviewer, and is the principal inventor of several IO related regular patents. He has authored more than 60 peer reviewed papers, principal inventor of several patents, and is an invited speaker to many vaccine and IO conferences. Pirouz completed his PhD in the Ottawa University, his postdoctoral fellowship on cancer vaccines in the City of Hope National Medical Centre and has served as a faculty in the University of Dalhousie and Miller School of Medicine University of Miami and later in industry, NGM Biopharmaceutical, Immunovaccine, and Nanovax (co-founder).

Immunotherapy Showcase:
JSR Life Sciences

JSR Life Sciences, and its affiliates, MBL Japan, MBLI, CrownBio, KBI, and Selexis aim to improve R&D and to shorten the drug development process.

Induction And Reversal Of T Cell Exhaustion In Vitro
Tumor specific T cells undergo levels of suppression leading to the T cell exhaustion (TEX). We present an in vitro TEX -like assay that divides hosts into “responders” and “non-responders” to immune checkpoint blockades. The assay, thus, is used for function-based screening of immunomodulator drug candidates.

 Session Abstract – PMWC Silicon Valley

The PMWC 2020 Immunotherapy Showcase will provide a 15-minute time slot for selected immunotherapy companies to present their latest technologies and advancements to an audience of leading investors, potential clients, and partners. We will hear from companies building new cell-based immunotherapies, work in the growing area of cancer vaccines, that help understand the relevance of the tumor microenvironment, accelerate the patient selection process, or otherwise work towards overcoming to challenges related to therapeutic discovery.